Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma PLC (~292)

  Print      Mail a friend       Annual reports

Thursday 13 December, 2001

Antisoma PLC

US Patent Approval

Antisoma PLC
13 December 2001

                    Antisoma receives US patent for Therex

13 December 2001, London, UK - Antisoma plc (LSE:ASM, NASD:ASOM), the UK-based
biopharmaceutical company specialising in the development of products for the
treatment of cancer, today announces that it has received notification of the
granting of a US patent for Therex, which is currently in Phase I studies for
the treatment of breast cancer.

Therex is a naked humanised antibody which attaches itself to cancer cells. It
helps components of the immune system, including natural killer cells, to find
and destroy the cancer cells.  The antibody recognizes MUC1, a cytokine-like
receptor which is highly expressed by most solid tumours.

The US patent covers antibodies that contain specified amino acid sequences
and that recognise MUC1.  The US patent will provide protection to Therex
until at least 2018.

Therex is initially being developed to treat women with breast cancer who have
relapsed following first line treatment. Breast cancer is the second most
common form of cancer, with around 500,000 women diagnosed with the disease
each year in North America, Europe and Japan.

Glyn Edwards, Chief Executive Officer of Antisoma, commented:

'The granting of the US patent for Therex is a further important strengthening
of our intellectual  property position. Therex is a highly promising approach
to the treatment of cancer, which is generating a lot of interest from
potential partners.'


Antisoma plc
Glyn Edwards, Chief Executive Officer           Tel: +44 (0)20 8799 8200

Financial Dynamics
Jonathan Birt                                   Tel: +44 (0)20 7831 3113

Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's
clinical development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.

Notes to Editors


Antisoma is a biopharmaceutical company developing novel products for the
treatment of cancer. Using its drug development experience, the Company aims
to produce safer and more effective tumour targeting therapies for
commercialisation by pharmaceutical partners. Antisoma acquires the rights to
promising new product candidates through partnerships with internationally
recognised academic or cancer research institutions. These include the lead
product candidate, pemtumomab, which was licensed from the Imperial Cancer
Research Fund and is currently in a Phase III study as adjuvant treatment for
ovarian cancer, with designated Orphan Drug status in the US and EU. There are
three additional products in the clinical pipeline, Therex, DMXAA and
TheraFab, and several pre-clinical programmes of which two, Angiomab and
Thioplatin, are expected to enter clinical studies in 2002. Visit for further information about Antisoma.


Nearly 500,000 women are diagnosed with breast cancer every year in North
America, Europe and Japan. Therex, based on a humanised form of the pemtumomab
monoclonal antibody, is under development initially to treat women with breast
cancer who have relapsed following first line treatment. The antibody targets
most epithelial cancer cells and since many breast cancers are epithelial,
Antisoma estimates that Therex could treat over 112,000 cases annually. This
would indicate a total market potential in excess of US$1 billion.

The Breast Cancer Biology Group at Guy's Hospital, funded by the ICRF who
originally developed Therex, conducted a Phase I clinical study to test the
product's safety and tolerability following repeat administration. Results
from 18 patients following treatment for primary breast cancer indicate that
the drug is well tolerated at the doses given. Antisoma is now progressing
Therex into the next Phase of clinical development and has contracted with
Lonza to provide clinical-grade material for the study, expected to start in


a d v e r t i s e m e n t